<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246816</url>
  </required_header>
  <id_info>
    <org_study_id>MP-101-CL-002OLE</org_study_id>
    <nct_id>NCT02246816</nct_id>
  </id_info>
  <brief_title>A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001</brief_title>
  <official_title>A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marathon Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marathon Pharmaceuticals, LLC</source>
  <brief_summary>
    <textblock>
      MP-101 will be evaluated in this study to see if it is safe and tolerable.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Transfer of IND to different marketing authorization representative.
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to 120 Days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <condition>Short Gut Syndrome</condition>
  <condition>SBS</condition>
  <condition>Short Gut</condition>
  <arm_group>
    <arm_group_label>All Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)</intervention_name>
    <description>0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)</description>
    <arm_group_label>All Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female adults, 18 years of age or older

          -  Have SBS that is inadequately controlled on current antidiarrheal medication (e.g.,
             loperamide or diphenoxylate), including subjects with ileostomies

          -  Must have been deemed a completer of study protocol MP-101-CL-001.

          -  Males or non-pregnant, non-lactating females who are postmenopausal, naturally or
             surgically sterile, or who agree to use effective contraceptive methods throughout the
             course of the study. Postmenopausal is defined as at least 12 months of natural
             spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral
             oophorectomy)

          -  Females of childbearing potential must agree to use 1 of the following acceptable
             birth control methods:

               -  Surgically sterile (hysterectomy or bilateral oophorectomy)

               -  Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior
                  to study initiation)

               -  Intrauterine device (IUD) in place for at least 3 months

               -  Abstinence (not having sexual intercourse)

               -  Barrier method (condom or diaphragm) with spermicide for at least 14 days prior
                  to screening and through study completion

               -  Stable hormonal contraceptive for at least 3 months prior to study and through
                  study completion

               -  Vasectomized partner

          -  Females of childbearing potential must have a negative serum human chorionic
             gonadotropin (hCG) pregnancy test at Visit 1.

          -  Be able to understand and provide signed informed consent

        Exclusion Criteria:

          -  Have any history of or active neurological, endocrine, cardiovascular, pulmonary,
             hematological, immunologic, psychiatric, or metabolic disease that is considered
             clinically significant, is not currently controlled by medication, and is stable as
             deemed by the Investigator

          -  Are currently taking antibiotics for bacterial overgrowth

          -  Have known or suspected pregnancy, planned pregnancy, or lactation

          -  Have a planned surgery during the course of the study

          -  Have a condition the Investigator believes would interfere with the ability to provide
             informed consent or comply with study instructions, or that might confound the
             interpretation of the study results or put the subject at undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Infectious Disease Infusion Center</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Center for Human Nutrition</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2014</study_first_posted>
  <last_update_submitted>February 16, 2015</last_update_submitted>
  <last_update_submitted_qc>February 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short Bowel Syndrome</keyword>
  <keyword>SBS</keyword>
  <keyword>Chronic Diarrhea</keyword>
  <keyword>Short Bowel</keyword>
  <keyword>Short Gut</keyword>
  <keyword>Short Gut Syndrome</keyword>
  <keyword>Anti-Diarrheal</keyword>
  <keyword>Opium Tincture</keyword>
  <keyword>loperamide</keyword>
  <keyword>diphenoxylate</keyword>
  <keyword>ileostomies</keyword>
  <keyword>tincture of opium</keyword>
  <keyword>DTO</keyword>
  <keyword>codeine</keyword>
  <keyword>morphine</keyword>
  <keyword>opiate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

